Allogeneic Cell Therapy for Adults With Hematologic Malignancies
This is a research study involving the treatment of leukemia or lymphoma (lymph gland
cancer) in adults who have leukemia or lymphoma that is unlikely to be cured with regular
anticancer drugs or radiation treatments. Intensive treatment with high doses of
chemotherapy followed by a bone marrow transplant (BMT) from an HLA-(tissue-type) matched
related donor would provide the best chance for cure of this leukemia or lymphoma. However,
the success of BMT from relatives is limited in patients who are older than 50 years and/or
have organ dysfunction by substantial complications due to the high dose chemotherapy
related toxicity, graft-versus- host disease (GVHD), and relapse. Patients eligible for this
study have an HLA matched sibling, but a BMT from the sibling would carry a high risk for
severe side effects due to the patient's age, and/or organ dysfunction.
Researchers are evaluating a new treatment for adult patients with leukemia and lymphoma
which involves regular dose chemotherapy and blood stem cell transplantation from an
HLA-matched relative, with injections of donor immune cells (a type of white blood cells)
given if you later relapse. In this study, the safety and feasibility of this treatment
strategy are being investigated.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine if conventional dose chemotherapy followed by allogeneic PBSC transplant and short course immunosuppression provide stable, sustained mixed donor-host chimerism.
Amelia Langston, MD
Emory University Winship Cancer Institute
United States: Institutional Review Board
|Emory University Winship Cancer Institute||Atlanta, Georgia 30322|